ag556

AG556 is a **selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase** and belongs to the tyrphostin family. It acts by blocking EGFR-mediated tyrosine phosphorylation, which regulates multiple downstream signaling pathways, including inflammatory and vascular responses. AG556 has been shown to block LPS-induced tumor necrosis factor alpha (TNF-α) production and to improve outcomes in animal models of septic shock and autoimmune myocarditis. Additionally, AG556 increases the activity of large conductance calcium-activated potassium (BK) channels by inhibiting EGFR tyrosine kinase, leading to enhanced vasodilation. It has been studied in experimental settings for its protective effect in arterial injury, multiorgan failure, and experimental autoimmune encephalomyelitis[1][3][4][5][7][8][9][10].

Brand names

AG556AG-556AG 556

Other names

(E)-AG 556tyrphostin AG556